Cargando…
B-Type Natriuretic Peptide Assay for the Diagnosis and Prognosis of Patent Ductus Arteriosus in Preterm Infants
BACKGROUND AND OBJECTIVES: Patent ductus arteriosus (PDA) is a significant cause of morbidity and mortality in preterm infants. Measurement of plasma B-type natriuretic peptide (BNP) has been reported to be a useful bedside screening tool for the presence of hemodynamically significant PDA (hsPDA) i...
Autores principales: | Kim, Joon Sik, Shim, Eun Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Cardiology
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318091/ https://www.ncbi.nlm.nih.gov/pubmed/22493614 http://dx.doi.org/10.4070/kcj.2012.42.3.192 |
Ejemplares similares
-
Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus
por: Jeong, Hyun Ah, et al.
Publicado: (2016) -
N-terminal pro-brain natriuretic peptide measurements in hemodynamically significant patent ductus arteriosus in preterm infants
por: Alenazi, Shehab Ahmed
Publicado: (2016) -
Plasma B-type natriuretic peptide cannot predict treatment response to ibuprofen in preterm infants with patent ductus arteriosus
por: Oh, Seong Hee, et al.
Publicado: (2020) -
Echocardiographic Evaluation of Patent Ductus Arteriosus in Preterm Infants
por: Arlettaz, Romaine
Publicado: (2017) -
Isoprostanes as Biomarker for Patent Ductus Arteriosus in Preterm Infants
por: Coviello, Caterina, et al.
Publicado: (2020)